🇪🇺 LUNSUMIO in European Union

EMA authorised LUNSUMIO on 3 June 2022

Marketing authorisation

EMA — authorised 3 June 2022

  • Application: EMEA/H/C/005680
  • Marketing authorisation holder: Roche Registration GmbH
  • Local brand name: Lunsumio
  • Indication: Lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies.
  • Pathway: conditional, orphan
  • Status: approved

Read official source →

LUNSUMIO in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in European Union

Frequently asked questions

Is LUNSUMIO approved in European Union?

Yes. EMA authorised it on 3 June 2022.

Who is the marketing authorisation holder for LUNSUMIO in European Union?

Roche Registration GmbH holds the EU marketing authorisation.